Precision therapies are often approved based on small trials, in specialized settings and use biomarkers as endpoints. Thus, despite their potentially high cost, the evidence of value is lacking which makes real-world evidence crucial. Join Darius Lakdawalla, director of research at the Schaeffer Center, in discussion with Kay Larholt, director of research at MIT NEWDIGS, and Megan O’Brien, executive director of the Center for Observational and Real World Evidence at Merck, for a webinar about how we should measure and leverage real-world data to assess the value of precision medicines.

his webinar is part of a four-part series on precision medicine. Funding for this project was made possible in part by a grant from the Agency for Healthcare Research and Quality (AHRQ) (1R13HS026821-01). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.